Clinical effect of budesonide/formoterol single inhaler combined with tiotropium bromide in stable chronic obstructive pulmonary disease / 药物评价研究

ABSTRACT

Objective To investigate the clinical effect of budesonide/formoterol single inhaler combined with tiotropium bromide in stable chronic obstructive pulmonary disease (COPD).Methods 80 cases of patients with stable COPD in China Aviation Industrial Xi'an Hospital from May 2014 to May 2016 were divided into observation group and control group,40 cases in each group.Patients in the control group were treated with budesonide/formoterol single inhaler,and in the observation group were treated with budesonide/formoterol single inhaler combined with tiotropium bromide.Compared the pulmonary function,life quality,serum levels of matrix metalloproteinases 9 (MMP-9) and interleukin 6 (IL-6),drug adverse reaction during the treatment and exacerbations episodes within the next six months.Results After treatment,the FEV1,FEV1/FVC,FEV1％ of two groups were significantly higher than before treatment (P ＜ 0.05),and in the observation group were significantly higher than that in control group (P ＜ 0.05).SGRQ scores,serum levels of MMP-9 and IL-6 of two groups were significantly lower than before treatment (P ＜ 0.05),and these indexes in the observation group were significantly lower than that in control group (P ＜ 0.05).The differences in the adverse reaction rate of two groups has no significant,the number of acute exacerbation in observation group were significantly lower than that of control group (P ＜ 0.05).Conclusion Budesonide/formoterol single inhaler combined with tiotropium bromide has remarkable clinical effect in stable COPD,and can effectively improve the pulmonary function,life quality,reduce the number of acute exacerbation,and reduce the serum levels of MMP-9,IL-6.